(CercleFinance.com) – Valneva drops by almost 7%, after the decision of its partner Pfizer to interrupt a significant percentage of participants in the United States enrolled in the phase 3 clinical study VALOR, which is evaluating its vaccine candidate VLA15 in Lyme disease.
These study participants are being discontinued due to violations of good clinical practice at certain clinical trial sites operated by a third-party clinical trial site operator, but not safety issues related to the investigational vaccine.
Pfizer has conducted a thorough review of operations and data collection at the sites in question. The clinical trial is nevertheless continuing on other sites and the American group continues to recruit new participants.